Potential efficacy of interleukin-1β inhibition in lung cancer

Research output: Contribution to journalComment / DebateOtherpeer-review

3 Citations (Scopus)
Original languageEnglish
Pages (from-to)1813-1814
Number of pages2
JournalThe Lancet
Volume390
Issue number10105
DOIs
Publication statusPublished - 21 Oct 2017

Cite this

@article{51f427dcd1a145beb20b343cdef9a660,
title = "Potential efficacy of interleukin-1β inhibition in lung cancer",
author = "Jenkins, {Brendan J.}",
year = "2017",
month = "10",
day = "21",
doi = "10.1016/S0140-6736(17)32289-4",
language = "English",
volume = "390",
pages = "1813--1814",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "10105",

}

Potential efficacy of interleukin-1β inhibition in lung cancer. / Jenkins, Brendan J.

In: The Lancet, Vol. 390, No. 10105, 21.10.2017, p. 1813-1814.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Potential efficacy of interleukin-1β inhibition in lung cancer

AU - Jenkins, Brendan J.

PY - 2017/10/21

Y1 - 2017/10/21

UR - http://www.scopus.com/inward/record.url?scp=85028323441&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(17)32289-4

DO - 10.1016/S0140-6736(17)32289-4

M3 - Comment / Debate

VL - 390

SP - 1813

EP - 1814

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10105

ER -